Abstract P192 Table 1 Functional respiratory imaging, body plethysmography and spirometry endpoints on Day 15 (end of treatment period)

Co-primary functional respiratory imaging endpoints				
	GFF MDI 14.4/ 10 µg	Placebo MDI	LSM ratio GFF vs placebo	p value
siVaw at TLC, mL/L	19/92	19/92	1.75 (1.65– 1.86)	<0.0001
n patients/n lobes	1.79 (1.48– 2.16)	1.02 (0.85– 1.24)		
Geometric LSM (95% CI)				
siRaw at TLC, kPa-s	19/92	19/92	0.29 (0.25– 0.33)	<0.0001
n patients/n lobes	0.09 (0.07– 0.11)	0.30 (0.23– 0.40)		
Geometric LSM (95% CI)				
Spirometry endpoints				
	GFF MDI 14.4/ 10 µg	Placebo MDI	LSM difference GFF vs placebo	p value
FEV₁, mL	19	19	443 (318– 569)	<0.0001
n patients	334 (245–422)	–110 (–198, –22)		
LSM change from baseline (95% CI)				
IC, mL	19	19	454 (209– 699)	0.0006
n patients	318 (144–491)	–136 (–310, 37)		
LSM change from baseline (95% CI)				
Body plethysmography endpoints				
	GFF MDI 14.4/ 10 µg	Placebo MDI	LSM ratio GFF vs placebo	p value
FRC, mL	19	19	0.87 (0.82– 0.92)	<0.0001
n patients	0.90 (0.86– 0.93)	1.03 (0.99– 1.07)		
LSM ratio to baseline (95% CI)				
RV, mL	19	19	0.78 (0.72– 0.84)	<0.0001
n patients	0.83 (0.79– 0.88)	1.07 (1.01– 1.13)		
LSM ratio to baseline (95% CI)				

CI, confidence interval; FEV₁, forced expiratory volume in 1 s; FRC, functional residual capacity; GFF, glycopyrronium/formoterol fumarate dihydrate; IC, inspiratory capacity; LSM, least squares mean; MDI, metered dose inhaler; RV, residual volume; siRaw, specific image-based airway resistance; siVaw, specific image-based airway volume; TLC, total lung capacity.

P193

THE DEGREE OF LUNG DESTRUCTION WITH EMPHYSEMA ON QUANTITATIVE LUNG CT SCANS VERSUS SUBJECTIVE AND OBJECTIVE IMPAIRMENT IN PATIENTS WITH ADVANCED EMPHYSEMA REFERRED FOR VOLUME REDUCTION THERAPIES

DT Betney, N Jarad. *Bristol Royal Infirmary, Bristol, UK*

10.1136/thoraxjnl-2017-210983.335

Background Quantitative CT (QCT) scans of the lungs have been recently introduced for directing clinicians to the most appropriate lobes needing treatment with lung volume reduction (LVR) therapies. Changes in QCT have been considered as a key marker of procedure success. However, despite procedures aiming to improve quality of life and exercise tolerance, there has been no understanding if the degree of

emphysema on QCTs correlates with the subjective and objective parameters used in patient selection for LVR.

Methods The pre-treatment QCT used was able to segment the lungs by tracing inter-lobar fissures thus providing data on the volume of each lobe. It was also able to digitally assess the proportion of emphysematous tissue area (defined by Hounsfield units of – 910 or less) in each lobe. Utilising these two properties we calculated the volume of the lungs affected by emphysema by the summation of the emphysema volumes in all lobes. Values and percentage predicted of FEV₁, residual volumes (RV) and gas transfer for carbon monoxide (TLco) were obtained from standard measurements; along with a 6 min walk distance (6'WD) and COPD assessment test (CAT) score. Spearman non-parametric correlation test was used to correlate emphysema volume with these parameters.

Results A total of 47 patients (19 female), mean age (SD) of 66.2 (8.9) years were included. Their mean (SD) FEV₁ was 0.81 L (0.28). There was no correlation between the total emphysema volume and CAT score ($r=-0.21$, $p=0.2$) or with 6'WD ($r=-0.34$, $p=0.054$). Total emphysema volume and the value of RV were strongly correlated; $r=0.68$, $p<0.0001$. There was no correlation with FEV₁ or TLco values. However, percentage of predicted values of lung function tests weakly correlated with total emphysema volume; for FEV₁ ($r=-0.36$, $p=0.01$), for RV ($r=0.34$, $p=0.02$) and for TLco ($r=-0.32$, $p=0.04$).

Conclusion The lack of strong correlation between anatomical changes and lung function is probably due to changes in airway diameter (as well as tissue destruction) which is not captured by QCT. To add to that, the lack of correlation with 6'WD or CAT score is probably due to non-pulmonary factors affecting the values of these two measurements.

P194

LOBAR PERFUSION UPTAKE SIGNIFICANTLY DIFFERS FROM LOBAR LUNG DESTRUCTION IN PATIENTS WITH ADVANCED EMPHYSEMA REFERRED FOR VOLUME REDUCTION THERAPIES

DT Betney, N Jarad. *University Hospital Bristol, Bristol, UK*

10.1136/thoraxjnl-2017-210983.336

Background Lung perfusion scan is widely undertaken as part of the assessment to select most affected lobes by emphysema prior to lung volume reduction (LVR) therapies by endo-bronchial valves, endo-bronchial coils and LVR surgery. More recently quantitative CT scans (QCT) have been introduced. QCTs quantify the degree of lung destruction by emphysema. To date there are no studies to evaluate whether lobar uptake of isotope by perfusion scan and areas of destruction on QCT's are closely correlated.

Methods Patients referred for LVR therapies at our hospital underwent perfusion scans using single-photon emission computerised tomography (SPECT) scans. The degree of uptake of isotope in each lobe is visually scored from 0–10, 0 representing low lobar isotope uptake and 10 high uptake. The degree of lobar low attenuation area (emphysema) has been assessed by a QCT scan. This scan provided data on the proportion of each lobe with attenuation of –910 Hounsfield Units (HU) and –950 HU. Uptake on SPECT has been correlated with emphysema score on QCTs.

Results A total 47 patients are included (20 female). Their mean age 66.2 years, and mean FEV₁ 30% of predicted